API | entolimod

entolimod Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Entolimod (CBLB502) is being developed by Cleveland Biolabs, Inc. for dual indications under the U.S. Food & Drug Administration’s (FDA) animal efficacy rule as a pivotal-stage radiation countermeasure, and under the FDA’s traditional drug approval pathway as a cancer treatment. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
entolimod

More Chemistry

Pharmacology

Mechanism of Action:
- Toll-like receptor 5 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

cblb502 | entolimod

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Verrucous (Phase 1)

Colorectal Neoplasms (Phase 2)

Graft vs Host Disease (Phase 1)

Healthy Volunteers (Phase 2)

Mucositis (Phase 1)

Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Tongue Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue